US › Healthcare

Curis Inc (CRIS)

US · Healthcare · Biotechnology

$0.91+7.06%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-8.6M

EPS

$-4.02

EPS estimate

$-5.70

EPS came in at -4.02 against a street estimate of -5.70 — a beat of 29.5%.

Key statistics

Market cap

$6.1M

P/E

0.7

Forward P/E

0.0

P/B

0.44

Book value

$2.41

EPS (TTM)

$1.32

52-week high

$28.40

52-week low

$0.33

50-day MA

$0.85

200-day MA

$8.59

Beta

3.25

Analyst view

Analysts rate Curis Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $42.67.

Shareholding

Insiders

5.77%

Institutions

10.61%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	81.60%
Cable Car Capital LLC	54.98%
CM Management, LLC	22.68%
Morgan Stanley - Brokerage Accounts	20.79%
Vanguard Capital Management, LLC	14.18%
Geode Capital Management, LLC	12.09%
M28 Capital Management LP	11.75%
F.L.Putnam Investment Management	10.13%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Curis Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.